<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03615300</url>
  </required_header>
  <id_info>
    <org_study_id>UC18OESI0055</org_study_id>
    <nct_id>NCT03615300</nct_id>
  </id_info>
  <brief_title>Predicting Long-term Outcomes After Cardiac Arrest by Using Serum NGAL</brief_title>
  <official_title>Predicting Long-term Outcomes After Cardiac Arrest by Using Serum NGAL: A Prospective, Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uijeongbu St. Mary Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Uijeongbu St. Mary Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was performed to determine the prognosis of patients after cardiac arrest using
      serum markers called NGAL. The initial NGAL values of patients with post-cardiac arrest
      syndrome are checked by blood tests, and the long-term neurological prognosis and survival
      rate are collected after 6 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Serum NGAL is currently being used as a test to determine the likelihood of developing renal
      failure. However, in a previous study, serum NGAL correlated with neurological prognosis in
      post cardiac arrest syndrome patients. This prospective study attempts to see the role of
      serum NGAL as a prognostic factor by including a sufficient number of patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 28, 2018</start_date>
  <completion_date type="Anticipated">May 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Long term neurologic outcome</measure>
    <time_frame>6 months</time_frame>
    <description>Patients' CPC score after 6 months (good outcome : CPC score 1, 2 / poor outcome : CPC score 3, 4, 5)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with Overall Survival at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>6-month survival rate of patients'</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">131</enrollment>
  <condition>Out-of-Hospital Cardiac Arrest</condition>
  <arm_group>
    <arm_group_label>good neurologic outcome</arm_group_label>
    <description>Patients with good neurological prognosis after 6 months (CPC 1, 2). serum NGAL is collected.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>poor neurologic outcome</arm_group_label>
    <description>Patients with poor neurological prognosis after 6 months (CPC 3, 4, 5). serum NGAL is collected.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>serum NGAL</intervention_name>
    <description>serum NGAL was measured at 0, 24, 48, and 72 hours after recovery of spontaneous circulation.</description>
    <arm_group_label>good neurologic outcome</arm_group_label>
    <arm_group_label>poor neurologic outcome</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult survivors after out-of-hopital cardiac arrest who underwent targeted temperature
        management and survived longer than 3 days.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients who underwent targeted temperature management after out-of-hospital
             cardiac arrest.

        Exclusion Criteria:

          -  Patients who did not survived 3 days after cardiac arrest.

          -  Pre-existing end-stage renal disease or dependence on renal replacement therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joo Suk Oh, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic University of Korea, Uijeongbu ST. Mary's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joo Suk Oh, MD PhD</last_name>
    <phone>82-10-4379-4197</phone>
    <email>erkeeper@catholic.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yoonho Kim, MD</last_name>
    <email>21300449@catholic.ac.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Uijeongbu St. Mary's Hospital</name>
      <address>
        <city>Uijeongbu-si</city>
        <state>Gyeonggi-do</state>
        <zip>11765</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joo Suk Oh, MD PhD</last_name>
      <phone>82-10-4379-4197</phone>
      <email>erkeeper@catholic.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>Yoonho Kim, MD</last_name>
      <email>21300449@catholic.ac.kr</email>
    </contact_backup>
    <investigator>
      <last_name>Joo Suk Oh, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jungtaek Park, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hyun Ho Jeong, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yoonho Kim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kyoung Ho Choi, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Youngmin Oh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Se Min Choi, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Doo Hyo Lee, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kiwook Kim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Elmer J, Jeong K, Abebe KZ, Guyette FX, Murugan R, Callaway CW, Rittenberger JC; Pittsburgh Post-Cardiac Arrest Service. Serum Neutrophil Gelatinase-Associated Lipocalin Predicts Survival After Resuscitation From Cardiac Arrest. Crit Care Med. 2016 Jan;44(1):111-9. doi: 10.1097/CCM.0000000000001357.</citation>
    <PMID>26457752</PMID>
  </reference>
  <results_reference>
    <citation>Park YR, Oh JS, Jeong H, Park J, Oh YM, Choi S, Choi KH. Predicting long-term outcomes after cardiac arrest by using serum neutrophil gelatinase-associated lipocalin. Am J Emerg Med. 2018 Apr;36(4):660-664. doi: 10.1016/j.ajem.2017.12.013. Epub 2017 Dec 7.</citation>
    <PMID>29317152</PMID>
  </results_reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>July 30, 2018</study_first_submitted>
  <study_first_submitted_qc>August 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2018</study_first_posted>
  <last_update_submitted>April 12, 2019</last_update_submitted>
  <last_update_submitted_qc>April 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Uijeongbu St. Mary Hospital</investigator_affiliation>
    <investigator_full_name>Joo Suk Oh, MD. PhD.</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Arrest</mesh_term>
    <mesh_term>Out-of-Hospital Cardiac Arrest</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

